Pathway Therapeutics Overview
- Year Founded
-
2008
- Status
-
Acquired/Merged
- Employees
-
40
- Latest Deal Type
-
M&A
Pathway Therapeutics General Information
Description
Developer of therapeutics against human diseases. The company offers PI3 kinase, an enzyme identified as active in cancer tumor development.
Contact Information
Corporate Office
- 409 Illinois Street
- San Francisco, CA 94158
- United States
Corporate Office
- 409 Illinois Street
- San Francisco, CA 94158
- United States
Pathway Therapeutics Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Merger/Acquisition | 14-Aug-2013 | Completed | Generating Revenue | |||
| 3. Debt - General | 05-Mar-2013 | Completed | Generating Revenue | |||
| 2. Early Stage VC (Series A1) | 25-May-2011 | $7.5M | $16.3M | Completed | Generating Revenue | |
| 1. Early Stage VC (Series A) | 10-Aug-2010 | $8.75M | $8.75M | Completed | Generating Revenue |
Pathway Therapeutics Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series A1 | ||||||||
| Series A |
Pathway Therapeutics Comparisons
Industry
Financing
Details
Pathway Therapeutics Competitors (18)
One of Pathway Therapeutics’s 18 competitors is Corbus Pharmaceuticals Holdings, a Formerly VC-backed company based in Norwood, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Corbus Pharmaceuticals Holdings | Formerly VC-backed | Norwood, MA | ||||
| Kite Pharma | Formerly VC-backed | Santa Monica, CA | ||||
| Adaptimmune Therapeutics | Formerly VC-backed | Abingdon, United Kingdom | ||||
| Inovio Pharmaceuticals | Corporation | Plymouth Meeting, PA | ||||
| Vertex Pharmaceuticals | Formerly VC-backed | Boston, MA |
Pathway Therapeutics Patents
Pathway Therapeutics Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2012135160-A1 | (alpha- substituted aralkylamino and heteroarylalkylamino) pyrimidinyl and 1,3,5 -triazinyl benzimidazoles, pharmaceutical compositions containing them, and these compounds for use in treating proliferative diseases | Inactive | 28-Mar-2011 | ||
| WO-2012135175-A1 | (alpha-substituted cycloalkylamino and heterocyclylamino) pyrimidinyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases | Inactive | 28-Mar-2011 | ||
| WO-2012135166-A1 | (fused ring arylamino and heterocyclylamino) pyrimidynyl and 1,3,5-triazinyl benzimidazoles, pharmaceutical compositions thereof, and their use in treating proliferative diseases | Inactive | 28-Mar-2011 | ||
| WO-2012044641-A1 | 1,3,5-triazinyl benzimidazole sulfonamides and their use in cancer therapy | Inactive | 29-Sep-2010 | ||
| EP-2532659-A1 | Pyrimidinyl and 1,3,5-triazinyl benzimidazoles and their use in cancer therapy | Inactive | 07-Jul-2009 | C07D487/04 |
Pathway Therapeutics Signals
Pathway Therapeutics Former Investors (6)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Aspire NZ Seed Fund | Venture Capital | Minority | ||
| Auckland UniServices | Corporate Venture Capital | Minority | ||
| Breast Cancer Research Trust | Corporation | Minority | ||
| GBS Venture Partners | Venture Capital | Minority | ||
| Talu Ventures | Venture Capital | Minority |
Pathway Therapeutics FAQs
-
When was Pathway Therapeutics founded?
Pathway Therapeutics was founded in 2008.
-
Where is Pathway Therapeutics headquartered?
Pathway Therapeutics is headquartered in San Francisco, CA.
-
What is the size of Pathway Therapeutics?
Pathway Therapeutics has 40 total employees.
-
What industry is Pathway Therapeutics in?
Pathway Therapeutics’s primary industry is Drug Discovery.
-
Is Pathway Therapeutics a private or public company?
Pathway Therapeutics is a Private company.
-
What is Pathway Therapeutics’s current revenue?
The current revenue for Pathway Therapeutics is .
-
How much funding has Pathway Therapeutics raised over time?
Pathway Therapeutics has raised $16.9M.
-
Who are Pathway Therapeutics’s investors?
Aspire NZ Seed Fund, Auckland UniServices, Breast Cancer Research Trust, GBS Venture Partners, and Talu Ventures are 5 of 6 investors who have invested in Pathway Therapeutics.
-
Who are Pathway Therapeutics’s competitors?
Corbus Pharmaceuticals Holdings, Kite Pharma, Adaptimmune Therapeutics, Inovio Pharmaceuticals, and Vertex Pharmaceuticals are some of the 18 competitors of Pathway Therapeutics.
-
When was Pathway Therapeutics acquired?
Pathway Therapeutics was acquired on 14-Aug-2013.
-
Who acquired Pathway Therapeutics?
Pathway Therapeutics was acquired by VetDC.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process